Live
- Per capita availability of fruits, vegetables increases in India
- FII buying reaches Rs 22,765 crore in Dec as economic growth stays resilient
- National Energy Conservation Day 2024: Date, Importance, and Easy Ways to Save Energy
- Gastronomic trouble: After 'disappearing' samosas Himachal CM in row over red jungle fowl
- Meaningful dialogue a priceless jewel of democracy: Jagdeep Dhankhar
- CM Revanth Reddy Advocates for Gurukuls as Talent Development Centers
- Zepto’s expenses surge over 71 pc in FY24, losses at Rs 1,248 crore
- Tim Southee matches Chris Gayle's six-hitting record in his farewell Test
- AP Mnister Ponguru Narayana Inspects Highway Connectivity Roads to Amaravati
- Reduced inflow: Water levels in Chembarambakkam, Poondi reservoirs drop
Phase-III clinical trial for Covaxin begins at NIMS in Hyderabad
Phase-III clinical trial for Covaxin begins at NIMS in Hyderabad
The Phase-III human clinical trails for Covaxin has begun at Nizam's Institute of Medical Sciences (NIMS) in Hyderabad on Monday.
The Phase-III human clinical trails for Covaxin has begun at Nizam's Institute of Medical Sciences (NIMS) in Hyderabad on Monday. A medical team at NIMS said that the vaccine will be given for 600 volunteers in the phase-III and will be monitored closely.
Phase-I and II trails have said to be successful as no volunteer developed any sign of illness. The Indian Council of Medical Research (ICMR) is planning to bring the vaccine by February. The vaccine is being jointly developed by Bharat Biotech and ICMR.
Bharat Biotech approached Drugs Controller General of India (DCGI) on October 2 for the phase-III trails of Covaxin and the permission was accorded at SEC meeting held in New Delhi on October 19.
The phase-III human trails of Covaxin are being carried out at 19 places including Delhi, Mumbai, Patna, Odisha and Lucknow.
